Liminatus Pharma (LIMN) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Senti Biosciences is the larger company by market cap ($9.8 million vs $5.1 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | SNTI |
|---|---|---|
| Share price | $3.76 | $0.3144 |
| Market cap | $5.05M | $9.79M |
| 1-day change | +1.90% | -2.27% |
| YTD return | — | -69.07% |
| 1-year return | — | -81.93% |
| 5-year return | — | -99.68% |
| EPS (TTM) | $-23.50 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $2.88 |
| 52-week low | $3.29 | $0.29 |
| Distance from 52-week high | -97.34% | -89.08% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +4193.89% |
| Average volume | 453.28K | 573.78K |
| Shares outstanding | 1.34M | 31.15M |
| Employees | 1 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
LIMN vs SNTI FAQ
Which is bigger, Liminatus Pharma or Senti Biosciences?
Senti Biosciences (SNTI) is larger, with a market capitalization of $9.79M compared with $5.05M for Liminatus Pharma (LIMN).
Are Liminatus Pharma and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.